自身免疫性肝炎和原发性胆汁性肝硬化患者检测可溶性细胞间黏附分子1的临床价值

叶青; 韩涛; 李宁

doi:10.3969/j.issn.1001-5256.2014.05.008

自身免疫性肝炎和原发性胆汁性肝硬化患者检测可溶性细胞间黏附分子1的临床价值

DOI: 10.3969/j.issn.1001-5256.2014.05.008

1. 天津市第三中心医院肝内科
2. 天津医科大学总医院核医学科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2535
- HTML全文浏览量: 19
- PDF下载量: 632
- 被引次数: 0
出版历程
- 收稿日期: 2013-12-25
- 出版日期: 2014-05-20

Clinical value of serum soluble intercellular adhesion molecule-1 in patients with primary biliary cirrhosis and autoimmune hepatitis

Department of Hepatology, Tianjin Third Central Hospital

摘要

摘要:
目的探讨原发性胆汁性肝硬化（PBC）和自身免疫性肝炎（AIH）患者中检测可溶性细胞间黏附分子1（sICAM-1）的临床价值。方法选择2012年6月-2013年9月住院及门诊就诊的PBC患者61例,其中初发患者29例,缓解期患者21例,复发患者11例;AIH患者共59例,其中初发患者26例,缓解期患者20例,复发患者13例。健康对照50例。血清sICAM-1测定方法为双抗体夹心酶联免疫吸附法,采用生物化学酶法测定血清ALT、TBil。各组间比较采用方差分析,相关性采用Pearson相关分析。结果PBC患者中,初发组和复发组sICAM-1水平均明显高于缓解组和对照组（P均=0.000）;初发组和复发组之间sICAM-1水平差异无统计学意义（P=0.484）;缓解组sICAM-1水平高于对照组（P=0.000）;AIH患者中,初发组和复发组sICAM-1水平均明显高于缓解组和对照组（P均=0.000）;初发组和复发组之间sICAM-1水平差异无统计学意义（P=0.802）;缓解组和对照组之间sICAM-1水平差异无统计学意义（P=0.281）;PBC、AIH患者血清sICAM-1与ALT呈正...
- 胞间粘附分子1 /
- 肝硬化,胆汁性 /
- 肝炎,自身免疫性
Abstract:
Objective To investigate the clinical value of serum soluble intercellular adhesion molecule- 1 ( sICAM- 1) in patients with primary biliary cirrhosis ( PBC) and autoimmune hepatitis ( AIH) . Methods Sixty- one PBC patients and 59 AIH patients, who were hospitalized or visited the outpatient department from June 2012 to September 2013, as well as 50 healthy controls, were included in the study. The PBC patients included 29 incipient cases, 21 cases in remission, and 11 recurrent cases; the AIH patients included 26 incipient cases, 20 cases in remission, and 13 recurrent cases. Serum sICAM- 1 level was measured by double- antibody sandwich enzyme- linked immunosorbent assay, and serum levels of alanine aminotransferase ( ALT) and total bilirubin ( TBil) were determined by biochemical enzyme assay. Comparison between groups was made by analysis of variance; Pearson correlation analysis was performed. Results Among PBC patients, the incipient group and recurrent group had significantly higher serum sICAM- 1 levels than the remission group and control group ( P = 0. 000 for all) ; there was no significant difference in serum sICAM- 1 level between the incipient group and recurrent group ( P = 0. 484) ; the remission group had a significantly higher serum sICAM- 1 level than the control group ( P = 0. 000) . Among AIH patients, the incipient group and recurrent group had significantly higher serum sICAM- 1 levels than the remission group and control group ( P = 0. 000 for all) ; there was no significant difference in serum sICAM- 1 level between the incipient group and recurrent group ( P = 0. 802) ; no significant difference in serum sICAM- 1 level was seen between the remission group and control group ( P = 0. 281) . For patients with PBC and AIH, serum sICAM- 1 level was positively correlated with serum levels of ALT ( r = 0. 664, P = 0. 000; r = 0. 784, P = 0. 000) and TBil ( r = 0. 715, P = 0. 000; r = 0. 580, P = 0. 000) . Conclusion Serum sICAM- 1 may be involved in the immunologic injury in PBC and AIH. In patients with PBC and AIH, the elevation of serum sICAM- 1 level is closely correlated with the severity of liver damage. Clinical monitoring of serum sICAM- 1 level may play an important role in severity assessment, prognostic evaluation, and therapy guidance among patients with autoimmune liver diseases.
- intercellular adhesion molecule-1 /
- liver cirrhosis, biliary /
- hepatitis, autoimmune

HTML全文

参考文献(20)

[1]JUBLANC C, BEAUDEUX JL, AUBART F, et al.Serum levels of adhesion molecules ICAM-1 and VCAM-1 and tissue inhibitor of metalloproteinases, TIMP-1 are elevated in patients with autoimmune thyroid disorders:relevance to vascular inflammation[J].Nutr Metab Cardiovasc Dis, 2011, 21 (10) :817-822.

[2]JAIN A, SAXENA S, KHANNA VK.Status of serum VEGF and ICAM-1 and its association with external limiting membrane and inner segment-outer segment junction disruption in type 2 diabetes mellitus[J].Mol Vis, 2013, 4 (19) :1760-1768.

[3]EFE C, WAHLIN S, OZASLAN E, et al.Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases[J].Eur J Gastroenterol Hepatol, 2012, 24 (5) :531-534.

[4]NISHIO A, KEEFFE EB, GERSHWIN ME.Immunopathogenesis of primary biliary cirrhosis[J].Semin Liver Dis, 2002, 22 (3) :291-302.

[5]YANG LL, BAO QD, CUI DL, et al.Expression of NF-κB and its regulation products in experimental autoimmune hepatitis and its significance[J].World Chin J Dig, 2008, 16 (8) :892-895. (in Chinese) 杨兰兰, 鲍启德, 崔东来, 等.核因子-κB及其调控产物在实验性自身免疫性肝炎中的表达及意义[J].世界华人消化杂志, 2008, 16 (8) :892-895.

[6]OZASLAN E, EFE C, HEURGU-B, ERLOT A, et al.Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis[J].Clin Gastroenterol Hepatol, 2013, Sep 26.[Epub ahead of print]

[7]ODZE RD, GOLDBLUM JR.Surgical pathology of the G I tract, liver, biliary tract and pancreas[M].Philadelphia, PA:Saunders Elesvier, 2009:1035-1043.

[8]HLINDOR KDH, HGERSHWIN MEH, HPOUPON RH, et al.Primary biliary cirrhosis[J].Hepatology, 2009, 50 (1) :291-308.

[9]HMANNS MPH, HCZAJA AJH, HGORHAM JDH, et al.Diagnosis and management of autoimmune hepatitis[J].Hepatology, 2010, 51 (6) :2193-2213.

[10]KANA I, TAKESHI K, HIROYUKI I, et al.Induction of ICAM-1 and VCAM-1 on the mouse lingual lymphatic endothelium with TNF-α[J].Acta Histochem Cytochem, 2008, 41 (5) :115-120.

[11]BLAND K, LAPIERRE P, DJILALI-SAIAH I, et al.Liver restores immune homeostasis after local inflammation despite the presence of autoreactive T cells[J].PLoS One, 2012, 7 (10) :e48192.

[12]ABDALLA A, SHEESHA AA, SHOKEIR M, et al.Serum intercellular adhesion molecule-I in children with chronic liver disease:relationship to disease activity[J].Dig Dis Sci, 2002, 47 (6) :1206-1208.

[13]TORTORELLA C, SACCO R, ORLANDO P, et al.sICAM-1, sCD95 and sCD95L levels in chronic liver diseases of different etiology[J].Immunopharmacol lmmunotoxicol, 2000, 22 (1) :19-33.

[14]SIMPSON KJ, JONES AL, FORBES HA, et al.Soluble adhesion molecules and interleukin-2 receptor concentrations in patients with autoimmune chronic hepatitis[J].Eur J Gastroenterol Hepatol, 1995, 7 (5) :455-460.

[15]BUMGARDNER GL, LI J, APTE S.Effect of tumor necrosis factor alpha and intercellular adhesion molecule-1 expression on immunogenicity of murine liver cells in mice[J].Hepatology, 1998, 28 (2) :466-474.

[16]THOMSON AW, SATOH S, NUSSLER AK, et al.Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokinestimulated human hepatocytes[J].Clin Exp Immunol, 1994, 95 (1) :83-90.

[17]BRUNO CM, SCIACCA C, CILIO D, et al.Circulating adhesion molecules in patients with virus-related chronic diseases of the liver[J].World J Gastroenterol, 2005, 11 (29) :4566-4569.

[18]HYOKOMORIH HH, HHODAH HMH, HOGIH HMH, et al.Expression of adhesion molecules on mature cholangiocytes in canal of Hering and bile ductules in wedge biopsy samples of primary biliary cirrhosis[J].World J Gastroenterol, 2005, 11 (28) :4382-4389.

[19]CZAJAH AJ.Autoimmune liver diseaseH[J].Curr Opin Gastroenterol, 2000, 16 (3) :262-270.

[20]WANG TL, ZHAO XY.Pathological features of autoimmune hepatitis[J].J Clin Hepatol, 2011, 27 (6) :577-580. (in Chinese) 王泰龄, 赵新颜.自身免疫性肝炎的病理特点[J].临床肝胆病杂志, 2011, 27 (6) :577-580.

施引文献

资源附件(0)

访问统计